Iovance Biotherapeutics (NASDAQ:IOVA) and Coherus Biosciences (NASDAQ:CHRS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.
This table compares Iovance Biotherapeutics and Coherus Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
95.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 99.2% of Coherus Biosciences shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 18.2% of Coherus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Iovance Biotherapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Coherus Biosciences has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Iovance Biotherapeutics and Coherus Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iovance Biotherapeutics currently has a consensus target price of $30.20, suggesting a potential upside of 26.31%. Coherus Biosciences has a consensus target price of $30.17, suggesting a potential upside of 56.87%. Given Coherus Biosciences’ higher possible upside, analysts plainly believe Coherus Biosciences is more favorable than Iovance Biotherapeutics.
Earnings and Valuation
This table compares Iovance Biotherapeutics and Coherus Biosciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Iovance Biotherapeutics||N/A||N/A||-$123.58 million||($1.27)||-18.83|
|Coherus Biosciences||$1.56 million||854.74||-$209.34 million||($3.22)||-5.97|
Iovance Biotherapeutics has higher earnings, but lower revenue than Coherus Biosciences. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Coherus Biosciences, indicating that it is currently the more affordable of the two stocks.
Coherus Biosciences beats Iovance Biotherapeutics on 6 of the 11 factors compared between the two stocks.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
About Coherus Biosciences
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.